Galenica Reports Revenue Growth for the First Nine Months of 2026

Galenica reported a 5.7% increase in group sales for the first nine months of 2026, reaching 3.17 billion Swiss francs, driven by its pharmacy business and home care division. Despite this revenue growth, the company's stock declined. Galenica has reaffirmed its financial targets for the full year.